You're totally right about that. The market cap is actually unbelievably high considering the poor rollout after data lock, the OTC MIA management and their lousy track record, lack of institutional holdings, endless dilution, and failure to properly assign CDMO's to their common shareholders. It's difficultly to understand why / how it's sitting at $800M??...